Document:

Employment Agreement between the Registrant and the VP & President of Caremark

 Exhibit 10.34 
 EMPLOYMENT AGREEMENT 
 This Employment Agreement is entered into by and
between CVS Caremark Corporation, a Delaware corporation (the “Company” or “CVS”), and Per G.H. Lofberg (the “Executive”). 
 WHEREAS, the Company and Executive desire to enter into an agreement setting forth the terms of Executive’s employment as Executive Vice President, CVS Caremark Corporation and President, Pharmacy
Benefit Services; 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein and for other good and valuable
consideration, the receipt of which is mutually acknowledged, the Company and Executive (individually a “Party” and together the “Parties”) agree as follows: 

 

	1.	Term of Agreement. 

 (a)
The term of this Agreement shall commence on January 1, 2010 (the “Effective Date”) and end on December 31, 2012 (the “Term of Agreement”), unless terminated earlier in accordance herewith. 

(b) Effect of a Change in Control. In the event of a Change in Control (as that term is defined in the CVS Caremark Corporation
Change in Control Agreement executed by Executive (the “CIC Agreement”), this entire Agreement, including Section 5, shall terminate immediately and shall have no further force or effect. 

 

	2.	Nature of Employment, Duties and Responsibilities. 

 (a) Generally. Executive is employed on an at-will basis by the Company or one of its subsidiaries, and the transfer of Executive’s employment to any of the Company’s operating
subsidiaries shall not be deemed a termination of employment, provided that the subsidiary that employs Executive shall directly or indirectly control substantially all of the Company’s pharmacy benefits management business. The Company shall
have the right to terminate Executive’s employment at any time for any reason or no reason without any obligation to Executive except as set forth in Section 4 of this Agreement. Executive shall have the right to terminate his employment
at any time for any reason or no reason, and shall have the rights and obligations set forth in this Agreement and the applicable benefit and compensation plans and equity grant agreements. 

(b) Duties. Executive shall have and perform such duties, responsibilities, and authorities as are specified by the Company from
time to time and as are consistent with his position as Executive Vice President, CVS Caremark and President, Pharmacy Benefit Services. Executive shall devote substantially all of his business time and attention (except for periods of vacation or
absences approved by the Company), and his best efforts, abilities, experience, and talent to the business of the Company. Notwithstanding the foregoing, this Agreement shall not preclude Executive from (i) serving on the boards of directors of
a reasonable number of other corporations or the boards of a reasonable number of trade associations and/or charitable organizations, (ii) engaging in charitable activities and community affairs, and (iii) managing his personal investments
and affairs, provided that such activities do not materially interfere with the proper performance of Executive’s duties and responsibilities under this Agreement, and further provided that such activities do not violate the Executive Covenants
set forth in Section 5 of this Agreement. The Company acknowledges that Executive serves on the Board of Directors of InVentiv Health, Inc. and XenoPort, Inc. which, as of the Effective Date, does not violate the Executive Covenants.

  

	3.	Compensation and Benefits  

(a) Base Salary. The Executive shall be paid an annualized salary (“Base Salary”), payable in accordance with the regular
payroll practices of the Company. The Executive’s initial Base Salary pursuant to this Agreement shall be $900,000.00, subject to periodic review and possible increase by the Company, but the Base Salary shall not be decreased. 

  
 1 

 (b) Bonus Program. The Executive shall be eligible to participate in the
Company’s annual Management Incentive Plan (the “MIP”). Payment of annual incentive awards shall be determined in accordance with the MIP. The Executive’s target bonus opportunity under the MIP shall be 130% of Base Salary.

 (c) Stock Options and Restricted Stock Units. The Executive shall be eligible to participate in the Company’s
stock option and restricted stock unit programs. Awards shall be governed by the CVS Caremark Corporation 1997 Incentive Compensation Plan, as amended, or any successor plan (collectively, the “ICP”) and the applicable award agreements.
The Executive’s annual equity value target shall be $2,000,000.00, provided that the actual value of the grant shall be determined by the Company in its sole discretion. The annual equity grant for Executive shall be granted fifty per cent
(50%) in stock options and fifty per cent (50%) in restricted stock units, and the grant agreements for 2010 shall be substantially in the forms attached hereto. 
 (d) Long-Term Incentive Plan. The Executive shall be entitled to participate in the Company’s Long-Term Incentive Plan (“LTIP”) for the period from January 1, 2010 through
December 31, 2012, with a target award of $3,000,000.00, and the Company may, in its sole discretion, offer Executive the opportunity to be eligible for LTIP awards in subsequent performance periods. All LTIP awards will be governed by the
terms of the LTIP. 
 (e) Sign-On Investment Opportunity. Executive will be entitled to participate in the Company’s
Partnership Equity Program (“PEP”) and shall be credited with an initial pre-tax investment of $1,500,000.00. 
 (f)
Employee Benefit Programs. During the Term of Agreement, the Executive shall be entitled to participate in such employee retirement and welfare benefit plans and programs of the Company as are made available to the Company’s
similarly-situated executives (as determined by the Company) or to its employees generally, as such plans or programs may be in effect from time to time, including, without limitation, health, medical, dental, long-term disability, and life
insurance plans. The Company reserves the right to suspend, amend, or terminate any benefit plans or programs at any time in its sole discretion. 
  

	4.	Termination of Employment. 

(a) Termination Due to Executive’s Resignation or Death. If Executive terminates his employment for any reason or if
Executive’s employment ends due to the Executive’s death, Executive will be entitled to receive his Base Salary earned through the last day of employment (the “Separation Date”). In addition, if Executive’s employment ends
due to the Executive’s death, the Company shall pay Executive’s estate a pro rata MIP award for the year in which Executive’s termination occurs, determined in accordance with the MIP and paid at such time as MIP awards are paid to
current employees generally. All other benefits due to Executive following the termination of employment will be determined in accordance with the applicable plans and policies and equity grant agreements. 

(b) Termination by the Company for Cause. 
 (i) If the Company terminates the Executive’s employment for “Cause”, Executive shall be entitled to receive his Base Salary earned through the Separation Date. All other benefits due to
Executive following the termination of employment will be determined in accordance with the applicable plans and policies and equity grant agreements. 
 (ii) “Cause” shall exist if the Executive: 
 (A)
willfully and materially breaches Section 5 of this Agreement or any contractual or common law obligations regarding protection of the Company’s confidential information, competition with the Company or solicitation of the Company’s
customers or employees; 
 (B) willfully and materially violates a material provision of the CVS Caremark Code of
Conduct or any of the Company’s other material policies; 

  
 2 

 (C) engages in serious misconduct unrelated to Executive’s job
(e.g., drug use or criminal conviction) and that is meaningfully detrimental to the Company’s reputation and/or to Executive’s ability to perform his duties; 

(D) willfully engages in conduct that is meaningfully detrimental to the Company’s reputation; or 

(E) engages in conduct that constitutes willful gross neglect or willful gross misconduct in carrying out his duties to
the Company. 
 (c) Termination by the Company Without Cause or by Executive for Good Reason. 

(i) Severance. If Executive’s employment is terminated by the Company under circumstances that constitute a
“Termination Without Cause” or by the Executive under circumstances that constitute a “Termination by Executive for Good Reason,” each as defined below, then Executive shall be entitled to and his sole remedies under this
Agreement shall be: 
 (A) Base Salary earned through the Separation Date and benefits due to Executive upon
termination in accordance with the plans and policies of the Company; 
 (B) severance pay in the form of
Executive’s Base Salary, paid on a monthly basis at the monthly rate in effect on the Separation Date, for a period of 12 months (the “Severance Period”); 

(C) pro rata MIP award for the year in which Executive’s termination occurs, determined in accordance with the MIP
and paid at such time as awards are paid to current employees generally; 
 (D) treatment of existing stock
option, restricted stock unit, LTIP and PEP awards in accordance with the ICP and the award agreements and plans, including any provisions relating to continued vesting during the Severance Period; 

(E) continued participation in all medical, dental and vision insurance plans pursuant to COBRA (subject to
Executive’s continued contribution at the same contribution rate as current employees receiving like coverage) until the earlier of: (A) the end of the Severance Period; or (B) the date the Executive receives coverage under the plans
and programs of a subsequent employer; provided that in the event that Executive is entitled to such participation beyond the time that Executive may participate in the plans pursuant to COBRA, the Company shall pay to Executive a monthly
cash amount equal, on an after-tax basis, to the amount that the Company contributed on a monthly basis to continue Executive’s coverage under COBRA. 
 (ii) A “Termination Without Cause” means the Company terminates Executive’s employment with the employing entity in the absence of Cause, the Executive’s resignation or the
Executive’s death. 
 (iii) A “Termination by Executive for Good Reason” means the termination of
Executive’s employment at his initiative following the occurrence, without Executive’s written consent, of one or more of the following events (except as a result of a prior termination): (A) an assignment of any duties to Executive
which are materially inconsistent with Executive’s status as a member of the senior management of CVS Caremark; (B) a decrease in Executive’s annual Base Salary, or a decrease in his target annual incentive award opportunity below
130% of his Base Salary; or (C) Executive is required to perform substantially all of his duties at any Company location. Notwithstanding the foregoing, no termination of Executive’s employment shall constitute a Termination by Executive
for Good Reason unless Executive notifies the Company in writing no later than ninety (90) days after the initial existence of the applicable event described above and such event is not remedied by the Company within thirty (30) days of
the Company’s receipt of such notice from the Executive. 
 (iv) Release and Compliance With Executive
Covenants. Executive’s eligibility for and receipt of the payments and benefits set forth in this Section 4(c) is contingent on (A) Executive’s execution of the severance agreement provided by the Company (which will include
a full release of claims against the Company and reaffirmation of the Executive Covenants set forth in Section 5) within 30 days after the Separation Date and (B) Executive’s compliance with the Executive Covenants set forth in
Section 5. 

  
 3 

 (v) Exclusivity of Severance Payments. Upon termination of the
Executive’s employment during the Term of Agreement, Executive shall not be entitled to any severance payments or severance benefits from the Company or any payments by the Company on account of any claim by Executive of wrongful termination,
including claims under any federal, state or local human and civil rights or labor laws, other than the payments and benefits provided in this Section 4(c). 

(vi) Sunset of Severance Entitlement. Executive shall not be entitled to the benefits and payments referred to in
Section 4(c) above for any termination of employment that occurs after December 31, 2012. 
  

	5.	Executive Covenants. 

 (a)
Non-Competition. During the Executive’s employment with the Company or one of its subsidiaries and during the 24-month period following the termination of Executive’s employment for any reason (the “Non-Competition
Period”), Executive will not, directly or indirectly, engage in Competition with the Company. “Competition” shall mean engaging in any activity for a Competitor of the Company, whether as a principal, agent, partner, officer,
director, employee, independent contractor, investor, consultant or stockholder (except as a less-than one percent shareholder of a publicly traded company) or otherwise. A “Competitor” shall mean any person, corporation or other entity
(and its parents, subsidiaries, affiliates and assigns) doing business in any geographical area in which the Company or any of its subsidiaries or affiliates are doing or have imminent plans to do business, and which is engaged in the operation of:
(a) a retail business which includes or has imminent plans to include a pharmacy (i.e. the sale of prescription drugs) as an offering or component of its business, including but not limited to, chain drug store companies such as Walgreen
Co. and Rite Aid Company, mass merchants such as Wal-Mart Stores, Inc. and Target Corp., and food/drug combinations such as The Kroger Co. and Supervalu Inc.; and/or (b) a business which includes or has imminent plans to include mail order
prescription, specialty pharmacy and/or pharmacy benefits management or any other services offered by Caremark Rx, LLC as an offering or component of its business, such as Medco Health Solutions, Inc. or Express Scripts, Inc., and/or (c) a
business which includes or has imminent plans to include offering, marketing or the sale of basic acute health care services at retail or other business locations, similar to the services provided by MinuteClinic, LLC (and excluding hospitals,
private physicians’ offices or other businesses dedicated to the direct provision of health care services). During Executive’s employment by the Company or one of its subsidiaries and during the Non-Competition Period, Executive will not,
directly or indirectly, engage in any activity that involves providing audit review or other consulting or advisory services with respect to any relationship between the Company and any third party. 

(b) Non-Solicitation. Executive will not, directly or indirectly, during his employment or during the Non-Competition Period:
(a) solicit, accept, or attempt to solicit or accept business from any customer, prospective customer, consultant, joint venture partner, independent contractor, or supplier of the Company for the purpose of offering, selling or providing
products or services that, directly or indirectly, compete or interfere with the business of the Company; or (b) hire, solicit, or induce any employee of the Company or any of its subsidiaries to leave the employ of the Company or any of its
subsidiaries or to reduce the services that he or she provides to the Company or any of its subsidiaries. 
 (c)
Non-Disclosure of Confidential Information. 
 (i) Executive will not at any time, whether during or after
the termination of Executive’s employment, reveal to any person or entity any of the trade secrets or Confidential Information concerning the organization, business or finances of the Company or of any third party which the Company is under an
obligation to keep confidential, except as may be required in the ordinary course of performing Executive’s duties as an employee of the Company. The Company’s Confidential Information includes but is not limited to non-public information
such as computer code generated or developed by the Company; software or programs and related documentation; strategic compilations and analysis; strategic processes; business or financial methods, practices and plans; non-public pricing; operating
margins; marketing, merchandising and selling techniques and information; customer lists; details of customer agreements; pricing 

  
 4 

 
arrangements with drug manufacturers; pharmacy reimbursement rates; expansion strategies; real estate strategies; operating strategies; sources of supply; employee compensation and benefit plans,
and patient records (collectively, “Confidential Information”). Executive shall keep secret all such matters entrusted to him and Executive shall not use or attempt to use any Confidential Information on behalf of any person or entity
other than the Company, or in any manner which may injure or cause loss or may be calculated to injure or cause loss, whether directly or indirectly, to the Company. Excluded from the definition of Confidential Information is information
(A) that is or becomes part of the public domain, other than through the breach of this Agreement by Executive or (B) regarding the Company’s business or industry properly acquired by Executive in the course of his career as an
executive in the Company’s industry and independent of Executive’s employment by the Company. For this purpose, information known or available generally within the pharmacy benefit management and/or retail pharmacy industry shall be deemed
to be known or available to the public. 
 (ii) Further, during his employment, Executive shall not make, use or
permit to be used any notes, memoranda, reports, lists, records, drawings, sketches, specifications, software programs, data, documentation or other materials of any nature relating to any matter within the scope of the business of the Company or
concerning any of its dealings or affairs otherwise than for the benefit of Company. Executive shall not, after the termination of his employment, use or permit to be used any such notes, memoranda, reports, lists, records, drawings, sketches,
specifications, software programs, data, documentation or other materials. All of the foregoing shall be and remain the sole and exclusive property of the Company and, immediately upon the termination of his employment, Executive shall deliver all
of the foregoing, and all copies thereof, to the Company at its main office. 
 (d) Ownership and Return of the
Company’s Property. On or before the Separation Date, Executive shall return to the Company all property of the Company in Executive’s possession, custody or control, including but not limited to the originals and copies of any
information provided to or acquired by Executive in connection with the performance of his duties for the Company, such as files, correspondence, communications, memoranda, e-mails, slides, records, and all other documents, no matter how produced or
reproduced, all computer equipment, communication devices (including but not limited to any BlackBerry or other portable digital assistant or device), computer programs and/or files, and all office keys and access cards. It is hereby acknowledged
that all of said items are the sole and exclusive property of the Company. 
 (e) Rights to Inventions, Works.

 (i) Inventions Retained and Licensed. Executive has attached hereto, as Exhibit A, a list describing
all inventions, original works of authorship, developments, improvements, and trade secrets which were made by Executive prior to his employment with the Company (collectively referred to as “Prior Inventions”), which belong to Executive,
which relate to the Company’s proposed business, products or research and development, and which are not assigned to the Company hereunder; or, if no such list is attached, Executive represents that there are no such Prior Inventions. Executive
agrees that Executive will not incorporate, or permit to be incorporated, any Prior Invention owned by him or in which Executive has an interest into a Company product, process or machine without the Company’s prior written consent.
Notwithstanding the foregoing sentence, if, in the course of his employment with the Company, Executive incorporates into a Company product, process or machine a Prior Invention owned by Executive or in which Executive has an interest, the Company
is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to make, have made, modify, use and sell such Prior Invention as part of or in connection with such product, process or machine. 

(ii) Assignment of Inventions. Executive will promptly make full written disclosure to the Company, will hold in
trust for the sole right and benefit of the Company, and hereby assign to the Company, or its designee, all his right, title, and interest in and to any and all inventions, original works of authorship, developments, concepts, improvements, designs,
discoveries, ideas, trademarks or trade secrets, whether or not patentable or registrable under copyright or similar laws, which Executive may solely or jointly 

  
 5 

 
conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice, during the period of time Executive is in the employ of the Company (collectively referred
to as “Inventions”). All original works of authorship which are made by Executive (solely or jointly with others) within the scope of and during the period of Executive’s employment with the Company and which are protectable by
copyright are “works made for hire,” as that term is defined in the United States Copyright Act and as such are the sole property of the Company. Executive understands and agrees that the decision whether or not to commercialize or market
any Invention developed by Executive solely or jointly with others is within the Company’s sole discretion and for the Company’s sole benefit and that no royalty will be due to Executive as a result of the Company’s efforts to
commercialize or market any such Invention. 
 (iii) Maintenance of Records. Executive shall keep and
maintain adequate and current written records of all Inventions made by Executive (solely or jointly with others) during the term of his employment with the Company. The records will be in the form of notes, sketches, drawings, and any other format
that may be specified by the Company. The records will be available to and remain the sole property of the Company at all times. 
 (iv) Patent and Copyright Registrations. Executive shall assist the Company, or its designee, at the Company’s expense, in every proper way to secure the Company’s rights in the
Inventions and any copyrights, patents, mask work rights or other intellectual property rights relating thereto in any and all countries, including, but not limited to, the disclosure to the Company of all pertinent information and data with respect
thereto, the execution of all applications, specifications, oaths, assignments and all other instruments which the Company shall deem necessary in order to apply for and obtain such rights and in order to assign and convey to the Company, its
successors, assigns, and nominees the sole and exclusive rights, title and interest in and to such Inventions, and any copyrights, patents, mask work rights or other intellectual property rights relating thereto. Executive’s obligation to
execute or cause to be executed, when it is in Executive’s power to do so, any such instrument or papers shall continue after the termination of this Agreement. If the Company is unable because of Executive’s mental or physical incapacity
or for any other reason to secure Executive’s signature to apply for or to pursue any application for any United States or foreign patents or copyright registrations covering Inventions or original works of authorship assigned to the Company as
above, then Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as his/her agent and attorney in fact, to act for and in Executive’s behalf and stead to execute and file any such
applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent or copyright registrations thereon with the same legal force and effect as if executed by Executive. 

(v) Exception to Assignments. The provisions of this Agreement requiring assignment of Inventions to the Company
shall not apply to any invention that Executive has developed entirely on his own time without using the Company’s equipment, supplies, facilities, trade secret information or Confidential Information except for those inventions that either
(i) relate at the time of conception or reduction to practice of the invention to the Company’s business, or actual or demonstrably anticipated research or development of the Company or (ii) result from any work that Executive
performed for the Company. Executive will advise the Company promptly in writing of any inventions that Executive believes meets the foregoing criteria and is not otherwise disclosed on Exhibit A. 

(f) Cooperation. 
 (i) In the event Executive receives a subpoena, deposition notice, interview request, or any other inquiry, process or order relating to any civil, criminal or administrative investigation, suit,
proceeding or other legal matter relating to the Company from any investigator, attorney or any other third party, Executive agrees to promptly notify the Company’s Chief Legal Officer by telephone and in writing. Without limiting the
generality of the preceding sentence, in the event Executive receives a subpoena, deposition notice, interview request, or any other inquiry, process or order which requires or may reasonably be construed to require Executive to produce Confidential
Information, Executive shall promptly: (i) notify the Company’s Chief Legal Officer of the item, document, or information sought by such subpoena, 

  
 6 

 
deposition notice, interview request, or other inquiry, process or order; (ii) furnish the Company’s Chief Legal Officer with a copy of said subpoena, deposition notice, interview
request, or other inquiry, process or order; and (iii) provide reasonable cooperation with respect to any procedure that the Company may initiate to protect Confidential Information or other interests. If the Company objects to the subpoena,
deposition notice, interview request, inquiry, process, or order, Executive shall cooperate to ensure that there shall be no disclosure until the court or other applicable entity has ruled upon the objection, and then only in accordance with the
ruling so made. Any disclosure of Confidential Information that is legally required or may reasonably be construed to be required to be made, and that is made after following the procedures set forth above and in accordance with this
Section 5(f)(i) shall not be a breach of Section 5(c) of this Agreement. Nothing in this Agreement shall be construed to prohibit Executive from testifying truthfully in any legal proceeding. 

(ii) Executive shall cooperate fully with the Company, its subsidiaries and affiliates, and their legal counsel in
connection with any action, proceeding, or dispute arising out of matters with which Executive was directly or indirectly involved while serving as an employee of the Company and/or its subsidiaries or affiliates. This cooperation shall include, but
shall not be limited to, meeting with, and providing information to, the Company and its legal counsel, maintaining the confidentiality of any past or future privileged communications with the Company’s legal counsel (outside and in-house), and
making himself available to testify truthfully by affidavit, in depositions, or in any other forum on behalf of the Company. The Company agrees to reimburse Executive for any reasonable and necessary out-of-pocket costs associated with his
cooperation. 
  

	6.	Breach, Injunctive Relief, and Attorneys Fees. 

 Executive agrees that any breach of this Agreement by Executive will cause irreparable damage to the Company and that, in the event of such breach, the Company shall have, in addition to any and all
remedies of law, the right to seek an injunction, specific performance or other equitable relief to prevent the violation of Executive’s obligations hereunder, and without providing a bond to the extent permitted by the applicable rules of
civil procedure. Any breach by Executive shall immediately relieve the Company of any obligation to provide Executive with any post-termination payments or benefits set forth in Section 4(c). 

 

	7.	Miscellaneous 

 (a) No
Conflicting Agreements. Executive represents that the performance of Executive’s duties with the Company and Executive’s compliance with all of the terms of this Agreement does not and will not breach any agreement to keep in
confidence proprietary information acquired by Executive in confidence or in trust prior to Executive’s employment by the Company. 
 (b) Severability. Each provision herein shall be treated as a separate and independent clause, and the unenforceability of any one clause shall in no way impair the enforceability of any of the
other clauses herein. Moreover, if one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to scope, activity, subject or otherwise so as to be unenforceable at law, such provision or
provisions shall be construed by the appropriate judicial body by limiting or reducing it or them, so as to be enforceable to the maximum extent compatible with the applicable law. 

(c) Effect of Agreement on Other Benefits. Except as specifically provided in this Agreement, the existence of this Agreement
shall not be interpreted to preclude, prohibit or restrict the Executive’s participation in any other employee benefit or other plans or programs in which Executive currently participates. 

(d) Assignability; Binding Nature. This Agreement shall be binding upon and inure to the benefit of the Company, its successors
and assigns. The obligations and duties of Executive hereunder are personal and not assignable by Executive. 

  
 7 

 (e) Entire Agreement. This Agreement and the applicable benefit, equity and incentive
plans and equity grant agreements, contain the entire understanding and agreement between the Parties concerning the subject matter hereof and, as of the Effective Date, supersedes all prior agreements, understandings, discussions, negotiations and
undertakings, whether written or oral, between the Parties with respect thereto. 
 (f) Amendment or Waiver. No provision
in this Agreement may be amended unless such amendment is agreed to in writing and signed by the Executive and an authorized officer of the Company. Except as set forth herein, no delay or omission to exercise any right, power or remedy accruing to
any Party shall impair any such right, power or remedy or shall be construed to be a waiver of or an acquiescence to any breach hereof. No waiver by either Party of any breach by the other Party of any condition or provision contained in this
Agreement to be performed by such other Party shall be deemed a waiver of a similar or dissimilar condition or provision at the same or any prior or subsequent time. Any waiver must be in writing and signed by the Executive or an authorized officer
of the Company, as the case may be. 
 (g) Taxation. The Company makes no guarantees or representations with respect to
the taxability of any payments set forth herein. Nevertheless, the Executive and Company agree that it is the intent of the parties that this Agreement not violate any applicable provision of, or result in any additional tax or penalty under,
Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and that to the extent any provisions of this Agreement do not comply with such Section 409A the parties will make such changes as are mutually agreed
upon in order to comply with Section 409A. In all events, to the extent required to avoid a violation of the applicable rules under all Section 409A by reason of Section 409A(a)(2)(B)(i) of the Code, payment of any amounts subject to
Section 409A of the Code shall be delayed until the relevant date of payment that will result in compliance with the rules of Section 409A(a)(2)(B)(i) of the Code. 
 (h) Survivorship. Except as set forth in Section 1(b), the Executive Covenants set forth in Section 5 shall survive the Executive’s termination of employment, regardless of the
reason for such termination. 
 (i) Governing Law/Jurisdiction. This Agreement shall be governed by and construed and
interpreted in accordance with the laws of Rhode Island without reference to principles of conflict of laws. The Company and the Executive hereby consent to the jurisdiction of any or all of the following courts for purposes of resolving any dispute
under this Agreement: (i) the United States District Court for Rhode Island or (ii) any of the courts of the State of Rhode Island. The Company and the Executive further agree that any service of process or notice requirements in any such
proceeding shall be satisfied if the rules of such court relating thereto have been substantially satisfied. The Company and the Executive hereby waive, to the fullest extent permitted by applicable law, any objection which it or he may now or
hereafter have to such jurisdiction and any defense of inconvenient forum. 

  
 8 

 (j) Notices. Any notice given to a Party shall be in writing and shall be deemed to
have been given when delivered personally or sent by certified or registered mail, postage prepaid, return receipt requested, duly addressed to the Party concerned at the address indicated below or to such changed address as such Party may
subsequently give such notice of: 
  

			
	If to the Company:	  	CVS Caremark Corporation
		  	One CVS Drive
		  	Woonsocket, Rhode Island 02895
		  	Attention: Corporate Secretary
		
	If to the Executive:	  	Mr. Per G.H. Lofberg
		  	63 East 92nd Street
		  	New York, New York 10128
		
		  	with a copy to:
		
		  	Laurence M. Moss
		  	Schulte Roth & Zabel LLP
		  	919 Third Avenue
		  	New York, New York 10022

 (k)
Headings. The headings of the sections contained in this Agreement are for convenience only and shall not be deemed to control or affect the meaning or construction of any provision of this Agreement. 

(l) Counterparts. This Agreement may be executed in two or more counterparts. 

 

									
	PER G.H. LOFBERG	 		 	CVS CAREMARK CORPORATION
					
		 	/s/ Per G.H. Lofberg	 		 	By:	 	/s/ V. Michael Ferdinandi
		 		 		 	 Name:
 Title:
	 	 V. Michael Ferdinandi

Senior Vice President and
 Chief Human Resources
Officer

  

									
	Date:	 	                             
                                         
             	 		 	Date:	  	                             
                                         
                        

  
 9Change in Control Agreement

 Exhibit 10.35 

 

 

  
  

CVS CAREMARK CORPORATION 
 Change in Control Agreement for 
 Per G.H. Lofberg 

 
  
  

			
	CONFIDENTIAL	  	REVISED November 2009

							
	 	  	 	  	Page	 
			
	1.	  	Definitions	  	 	2	  
			
	2.	  	Term of Agreement	  	 	6	  
			
	3.	  	Entitlement to Severance Benefit	  	 	6	  
			
	4.	  	Confidentiality; Cooperation with Regard to Litigation; Non-disparagement	  	 	8	  
			
	5.	  	Non-solicitation	  	 	9	  
			
	6.	  	Remedies	  	 	10	  
			
	7.	  	Effect of Agreement on Other Benefits and Obligations	  	 	10	  
			
	8.	  	Not an Employment Agreement	  	 	10	  
			
	9.	  	Resolution of Disputes	  	 	10	  
			
	10.	  	Assignability; Binding Nature	  	 	10	  
			
	11.	  	Representation	  	 	11	  
			
	12.	  	Amendment or Waiver, Section 409A	  	 	11	  
			
	13.	  	Severability	  	 	11	  
			
	14.	  	Survivorship	  	 	11	  
			
	15.	  	Beneficiaries/References	  	 	11	  
			
	16.	  	Governing Law/Jurisdiction	  	 	12	  
			
	17.	  	Notices	  	 	12	  
			
	18.	  	Headings	  	 	12	  
			
	19.	  	Counterparts	  	 	13	  

  
 1 

 This Change in Control Agreement (“Agreement”) is effective as of January 1,
2010 between CVS Pharmacy, Inc. (“CVS”) and Per G.H. Lofberg (the “Executive”). 
 WHEREAS, the Board of
Directors (the “Board”) of CVS Caremark Corporation (“CVS Caremark” or the “Company”) believes it is necessary and desirable for the Company to be able to rely upon Executive to continue serving in his or her position
with the Company in the event of a pending or actual change in control of CVS Caremark; 
 WHEREAS, Executive is employed by a
Subsidiary of CVS Caremark, and this Agreement shall not alter Executive’s status as an employee at will; 
 NOW,
THEREFORE, in consideration of the promises and mutual covenants contained herein and for other good and valuable consideration, the receipt of which is mutually acknowledged, CVS and Executive (individually a “Party” and together the
“Parties”) agree as follows: 
  

	1.	Definitions. 

  

	 	a.	“Base Salary” shall mean Executive’s annual rate of base salary at the time of Executive’s termination of employment or, if greater, as in effect
immediately prior to a Change in Control. 

  

	 	b.	“Cause” shall exist if: 

  

	 	i.	Executive willfully and materially breaches Sections 4 or 5 of this Agreement; 

 

	 	ii.	Executive is convicted of a felony involving moral turpitude; or 

  

	 	iii.	Executive engages in conduct that constitutes willful gross neglect or willful gross misconduct in carrying out Executive’s duties under this Agreement, resulting,
in either case, in material harm to the financial condition or reputation of the Company. 

 For purposes of this
Agreement, an act or failure to act on Executive’s part shall be considered “willful” if it was done or omitted to be done by Executive not in good faith, and shall not include any act or failure to act resulting from any incapacity
of Executive. A termination for Cause shall not take effect absent compliance with the provisions of this paragraph. Executive shall be given written notice by the Company of its intention to terminate Executive’s employment for Cause, such
notice (A) to state in detail the particular act or acts or failure or failures to act that constitute the grounds on which the proposed termination for Cause is based and (B) to be given within 90 days of the Company’s learning of
such act or acts or failure or failures to act. Executive shall have 20 days after the date that such written notice has been given to Executive in which to cure such conduct, to extent such cure is possible. If Executive fails to cure such conduct,
Executive shall then be entitled to a hearing before the Committee, or an officer or officers designated by the Committee, at which Executive is entitled to appear. Such hearing shall be held within 25 days of such notice to Executive, provided
Executive requests such hearing within 10 days of the written notice from the Company of the intention to terminate Executive for Cause. If, within five days following such hearing, Executive is furnished written notice by the Committee confirming
that, in its judgment, grounds for Cause on the basis of the original notice exist, Executive shall thereupon be terminated for Cause. Executive’s right to cure in accordance with this provision applies only in the event of a Change in Control
as defined in Section 1(c) below and does not alter Executive’s “at will” employment status. 

  
 2 

	 	c.	A “Change in Control” shall be deemed to have occurred if: 

  

	 	(i)	any Person (other than (w) the Company, (x) any trustee or other fiduciary holding securities under any employee benefit plan of the Company, (y) any
company owned, directly or indirectly, by the stockholders of the Company immediately after the occurrence with respect to which the evaluation is being made in substantially the same proportions as their ownership of the common stock of the Company
immediately prior to such occurrence or (z) any surviving or resulting entity from a merger or consolidation referred to in clause (iii) below that does not constitute a Change in Control under clause (iii) below) becomes the
Beneficial Owner (except that a Person shall be deemed to be the Beneficial Owner of all shares that any such Person has the right to acquire pursuant to any agreement or arrangement or upon exercise of conversion rights, warrants or options or
otherwise, without regard to the sixty day period referred to in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company or of any subsidiary owning directly or indirectly all or substantially all of the consolidated
assets of the Company (a “Significant Subsidiary”), representing 30% or more of the combined voting power of the Company’s or such Significant Subsidiary’s then outstanding securities; 

 

	 	(ii)	during any period of twelve (12) consecutive months, individuals who at the beginning of such period constitute the Board, and any new director whose election by
the Board or nomination for election by the Company’s stockholders was approved by a vote of at least a majority of the directors then still in office who either were directors at the beginning of the twelve (12) month period or whose
election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the Board; 

  

	 	(iii)	the consummation of a merger or consolidation of the Company or any Significant Subsidiary with any other entity, other than a merger or consolidation which would
result in the voting securities of the Company or a Significant Subsidiary outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving or resulting
entity) more than 50% of the combined voting power of the surviving or resulting entity outstanding immediately after such merger or consolidation; or 

  

	 	(iv)	the consummation of a transaction (or series of transactions within a 12 month period) which constitutes the sale or disposition of all or substantially all of the
consolidated assets of the Company but in no event assets having a gross fair market value of less than 40% of the total gross fair market value of all of the consolidated assets of the Company (other than such a sale or disposition immediately
after which such assets will be owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the common stock of the Company immediately prior to such sale or disposition)

 For purposes of this definition: 

 

	 	(A)	 The term “Beneficial Owner” shall have the meaning ascribed to such term in Rule 13d-3 under the Exchange Act (including

  
 3 

	 	 
any successor to such Rule). 

  

	 	(B)	The term “Exchange Act” means the Securities Exchange Act of 1934, as amended from time to time, or any successor act thereto. 

 

	 	(C)	The term “Person” shall have the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections 13(d) and 14(d) thereof,
including “group” as defined in Section 13(d) thereof. 

  

	 	d.	“Committee” shall mean the Management Planning and Development Committee of the Board, or the corresponding committee of the board of directors of a successor
to CVS Caremark. 

  

	 	e.	“Company” shall mean, collectively, CVS Caremark and any Subsidiary or affiliate of CVS Caremark. 

 

	 	f.	“Confidential Information” shall have the meaning set forth in Section 4 below. 

 

	 	g.	“Constructive Termination Without Cause” shall mean a termination of the Executive’s employment at Executive’s initiative following the occurrence,
without the Executive’s written consent, of one or more of the following events (except as a result of a prior termination): 

  

	 	i.	an assignment of any duties to Executive that is inconsistent with Executive’s status as a member of the senior management of CVS Caremark;

  

	 	ii.	a decrease in Executive’s annual base salary or target annual incentive award opportunity; 

 

	 	iii.	any failure to secure the agreement of any successor to CVS Caremark to fully assume the Company’s obligations under this Agreement; or 

 

	 	iv.	a relocation of Executive’s principal place of employment more than 35 miles from Executive’s place of employment before such relocation.

  

	 	h.	“Disability” shall mean disability as that term is defined in the Company’s Long-Term Disability Plan. 

 

	 	i.	“Effective Date” shall have the meaning set forth in Section 2 below. 

 

	 	j.	“Original Term” shall have the meaning set forth in Section 2 below. 

 

	 	k.	“Renewal Term” shall have the meaning set forth in Section 2 below. 

 

	 	l.	“Severance Period” shall mean the period of 18 months following the termination of Executive’s employment with the Company. 

 

	 	m.	“Subsidiary” shall have the meaning set forth in Section 4 below. 

 

	 	n.	“Term” shall have the meaning set forth in Section 2 below. 

 

	 	o.	“termination of employment”, “employment is terminated” and other similar words shall mean with respect to Executive 

  
 4 

 (i) for any plan or arrangement that is subject to the rules of Section 409A of the
Internal Revenue Code (the “Code”) a “Separation from Service” as such term is defined in the Income Tax Regulations under Section 409A (the “409A Regulations”) of the Code as modified by the rules described below:

  

	 	(A)	except in the case where Executive is on a bona fide leave of absence pursuant to the Company’s policies as provided below, Executive is deemed to have incurred a
Separation from Service on a date if the company and Executive reasonably anticipate that the level of services to be performed by Executive after such date would be permanently reduced to 20% or less of the average services rendered by Executive
during the immediately preceding 36-month period (or the total period of employment, if less than 36 months), disregarding periods during which Executive was on a bona fide leave of absence; 

 

	 	(B)	if Executive is absent from work due to military leave, sick leave, or other bona fide leave of absence pursuant to the Company’s policies, Executive shall incur a
Separation from Service on the first date that the rules of (A), above, are satisfied following the later of (i) the six-month anniversary of the commencement of the leave or (ii) the expiration of Executive’s right, if any, to
reemployment under statute, contract or Company policy; 

  

	 	(C)	Executive shall be considered to continue employment and to not have a Separation from Service while on a bona fide leave of absence pursuant to the Company’s
policies if the leave does not exceed 6 consecutive months (12) months for a disability leave of absence) or, if longer, so long as the Executive retains a right to reemployment with the Company or an Affiliate under an applicable statute,
contract or Company policy. For this purpose, a “disability leave of absence” is an absence due to any medically determinable physical or mental impairment of Executive that can be expected to result in death or can be expected to last for
a continuous period of not less than 6 months, where such impairment causes the Participant to be unable to perform the duties of his job or a substantially similar job; 

 

	 	(D)	for purposes of determining whether another organization is an Affiliate of the Company, common ownership of at least 50% shall be determinative;

  

	 	(E)	the Company specifically reserves the right to determine whether a sale or other disposition of substantial assets to an unrelated party constitutes a Separation from
Service with respect to Executive providing services to the seller immediately prior to the transaction and providing services to the buyer after the transaction. Such determination shall be made in accordance with the requirements of
Section 409A of the Code; or 

  

	 	(ii)	for any plan or arrangement that is not subject to the rules of Section 409A of the Code, the complete cessation of providing service to the Company or any
Affiliate as an employee. 

  
 5 

	2.	Term of Agreement. 

 The
term of this Agreement shall commence on the date of this Agreement (the “Effective Date”) and end on the third anniversary of such date (the “Original Term”). The Original Term shall be automatically renewed for successive
one-year terms (the “Renewal Terms”) unless at least 180 days prior to the expiration of the Original Term or any Renewal Term, either Party notifies the other Party in writing that he/she or it is electing to terminate this Agreement at
the expiration of the then current Term. “Term” shall mean the Original Term and all Renewal Terms. If a Change in Control shall have occurred during the Term, notwithstanding any other provision of this Section 2, the Term shall not
expire earlier than two years after such Change in Control. 
  

	3.	Entitlement to Severance Benefit. 

  

	 	a.	Severance Benefit. In the event Executive’s employment with the Company is Terminated Without Cause, other than due to death, or Disability, or in the event
there is a Constructive Termination Without Cause within two years following a Change in Control, Executive shall be entitled to receive: 

  

	 	i.	Base Salary through the date of termination of Executive’s employment, which shall be paid in a cash lump sum not later than 15 days following Executive’s
termination of employment; 

  

	 	ii.	An amount equal to 1.5 times Executive’s Base Salary in effect on the date of termination of Executive’s employment (or in the event a reduction in Base
Salary is a basis for a Constructive Termination Without Cause, then the Base Salary in effect immediately prior to such reduction), payable in a cash lump sum promptly (but in no event later than 15 days) following Executive’s termination of
employment; 

  

	 	iii.	An amount equal to the sum of (A) the most recently established target annual cash incentive bonus amount, pro rated based on the portion of the performance year
that Executive has worked as of the date of Executive’s termination, plus (B) 25% of Base Salary (which represents an amount equal to the cash value of the target annual Performance-Based Restricted Stock unit award for the year in which
termination occurs), pro rated based on the portion of the performance year that Executive has worked as of the date of his/her termination. The Base Salary will be determined in accordance with Section 3.a.ii. Such payment of a pro rata annual
cash incentive bonus and cash in lieu of Performance-Based Restricted Stock will be payable in a cash lump sum promptly (but in no event later than 15 days) following Executive’s termination of employment; 

 

	 	iv.	An amount equal to 1.5 times the sum of (A) the most recently established target annual incentive cash bonus amount, plus (B) 25% of Base Salary (determined
in accordance with Section 3.a.ii above), payable in a cash lump sum promptly (but in no event later than 15 days) following the Executive’s termination of employment; 

 

	 	v.	Elimination of all restrictions on any restricted stock or restricted stock unit awards outstanding at the time of termination of employment (other than awards under
the Company’s Partnership Equity Program, which shall be governed by the terms of such awards); 

  

	 	vi.	 Immediate vesting of all outstanding stock options and the right to exercise such stock options for the remainder of the full term of such option
(other than awards 

  
 6 

	 	 
under the Company’s Partnership Equity Program, which shall be governed by the terms of such awards); 

 

	 	vii.	The balance of any incentive awards earned as of December 31 of the prior year (but not yet paid), which shall be paid in a single lump sum not later than 15 days
following Executive’s termination of employment; 

  

	 	viii.	Settlement of all deferred compensation arrangements in accordance with any then applicable deferred compensation plan or election form; 

 

	 	ix.	Continued participation in all medical, health and life insurance plans at the same benefit level at which Executive was participating on the date of termination of
Executive’s employment until the earlier of: 

  

	 	1.	the end of the Severance Period; or 

  

	 	2.	the date, or dates, Executive receives equivalent coverage and benefits under the plans and programs of a subsequent employer (such coverage and benefits to be
determined on a coverage-by-coverage, or benefit-by-benefit, basis); 

 provided that (1) if Executive is
precluded from continuing Executive’s participation in any employee benefit plan or program as provided in this clause (ix) of this Section 3.a, Executive shall receive cash payments equal on an after-tax basis to the cost to
Executive of obtaining the benefits provided under the plan or program in which Executive is unable to participate for the period specified in this clause (ix) of this Section 3.a, (2) such cost shall be deemed to be the lowest
reasonable cost that would be incurred by Executive in obtaining such benefit on an individual basis, and (3) payment of such amounts shall be made quarterly in advance; and 

 

	 	x.	other or additional benefits then due or earned in accordance with applicable plans and programs of the Company. 

 

	 	b.	Change in Control Best Payments Determination. In the event the Severance Benefits described in Section 3(a) are payable to Executive in connection with a
Change in Control and, if paid, could subject Executive to an excise tax under Section 4999 of the Internal Revenue Code (the “Excise Tax”), then notwithstanding the provisions of Section 3(a) the Company shall reduce the
Severance Benefits (the “Benefit Reduction”) under Section 3(a) by the amount necessary to result in the Executive not being subject to the Excise Tax if such reduction would result in the Executive’s “Net After-Tax
Amount” attributable to the Severance Benefits described in Section 3(a) being greater than it would be if no Benefit Reduction was effected. For this purpose “Net After-Tax Amount” shall mean the net amount of Severance Benefits
Executive is entitled to receive under this Agreement after giving effect to all Federal, state and local taxes which would be applicable to such payments, including, but not limited to, the Excise Tax. The determination of whether any such Benefit
Reduction shall be effected shall be made by a nationally recognized public accounting firm selected by the Company (the “Accounting Firm”) prior to the occurrence of the Change in Control and such determination shall be binding on both
Executive and the Company. In the event it is determined that a Benefit Reduction is required, such reduction of items described in Section 3(a) above shall be done first by reducing cash severance determined in accordance with
Section 3(a)(ii), 3(a)(iii) and 3(a)(iv); to the extent a further Benefit Reduction is necessary, then Severance Benefits will be reduced from the amounts determined in accordance with Section 3(a)(v) and 3(a)(vi), all as determined by the
Accounting Firm. 

  
 7 

	 	c.	No Mitigation; No Offset. In the event of any termination of employment under this Section 3, Executive shall be under no obligation to seek other
employment, and the amounts due Executive under this Agreement shall not be offset by any remuneration attributable to any subsequent employment that Executive may obtain. 

 

	 	d.	Nature of Payments. Any amounts due under this Section 3 are in the nature of severance payments considered to be reasonable by the Company and are not in
the nature of a penalty. 

  

	 	e.	Exclusivity of Severance Benefit. Upon termination of Executive’s employment following a Change in Control, Executive shall not be entitled to any severance
payments or severance benefits from the Company, or any other payments by the Company pursuant to any other agreement or arrangement between Executive and the Company, other than the Severance Benefit provided in this Section 3, except as
required by law. 

  

	 	f.	General Release of Claims. Executive agrees, as a condition of payment of the Severance Benefit provided for in this Section 3, that Executive will execute
within 60 days of Executive’s termination of employment a separation agreement, in a form reasonably satisfactory to the Company, that includes a general release of any and all claims arising out of Executive’s employment or termination of
employment with the Company, other than claims for (i) enforcement of this Agreement, (ii) enforcement of Executive’s rights under any of the Company’s incentive compensation, equity and/or employee benefit plans and programs to
which Executive is entitled under this Agreement, and (iii) any tort for personal injury not arising out of or related to Executive’s employment or termination of employment. 

 

	 	g.	Subject to the provisions of Section 12(b), all payments to be made pursuant to this Section 3 upon the termination of employment of Executive shall be made
or commence, as the case may be, within 75 days after the Executive’s termination of employment provided, however, that if such termination of employment is after October 15 of a year, the payment or first payment, as the case may be,
shall be made at the end of such 75 day period. 

  

	4.	Confidentiality; Cooperation with Regard to Litigation; Non-disparagement. 

 

	 	a.	During the Term and thereafter, Executive shall not, without the prior written consent of the Company, disclose to anyone (except in good faith in the ordinary course
of business to a person who will be advised by Executive to keep such information confidential) or make use of any confidential information except in the performance of Executive’s duties hereunder or when required to do so by legal process, by
any governmental agency having supervisory authority over the business of the Company or by any administrative or legislative body (including a committee thereof) that requires Executive to divulge, disclose or make accessible such information. In
the event that Executive is so ordered, Executive shall give prompt written notice to the Company in order to allow the Company the opportunity to object to or otherwise resist such order. 

 

	 	b.	 During the Term and thereafter, Executive shall not disclose the existence or contents of this Agreement beyond what is disclosed in the proxy
statement or documents filed with the government unless and to the extent such disclosure is required by law, by a governmental agency, or in a document required by law to be filed with a governmental agency or in connection with enforcement of
his/her rights under this Agreement. In the event that disclosure is so required, Executive shall give prompt written notice to the Company in order to allow the Company the opportunity to object to or otherwise resist such requirement. This
restriction shall not apply to such disclosure by Executive to members of his/her immediate family, his/her tax, legal or financial advisors, any lender, 

  
 8 

	 	 
or tax authorities, or to potential future employers to the extent necessary, each of whom shall be advised not to disclose such information. 

 

	 	c.	“Confidential Information” shall mean all information concerning the business of the Company or any Subsidiary relating to any of their products, product
development, trade secrets, customers, suppliers, finances, and business plans and strategies. Excluded from the definition of Confidential Information is information (i) that is or becomes part of the public domain, other than through the
breach of this Agreement by Executive or (ii) regarding the Company’s business or industry properly acquired by Executive in the course of Executive’s career as an Executive in the Company’s industry and independent of
Executive’s employment by the Company. For this purpose, information known or available generally within the trade or industry of the Company or any Subsidiary shall be deemed to be known or available to the public. 

 

	 	d.	“Subsidiary” shall mean any corporation or other business entity owned or controlled directly or indirectly by CVS Caremark. 

 

	 	e.	Executive agrees to cooperate with the Company, during the Term and thereafter (including following Executive’s termination of employment for any reason), by being
reasonably available to testify on behalf of the Company or any Subsidiary in any action, suit, or proceeding, whether civil, criminal, administrative, or investigative, and to assist the Company, or any Subsidiary, in any such action, suit, or
proceeding, by providing information and meeting and consulting with the Board or its representatives or counsel, or representatives or counsel to the Company, or any Subsidiary as requested; provided, however that the same does not materially
interfere with Executive’s then current professional activities. The Company agrees to reimburse Executive on an after tax basis, for all reasonable expenses actually incurred in connection with Executive’s provision of testimony or
assistance. 

  

	 	f.	Executive agrees that, during the Term and thereafter (including following Executive’s termination of employment for any reason) Executive will not make statements
or representations, or otherwise communicate, directly or indirectly, in writing, orally, or otherwise, or take any action which may, directly or indirectly, disparage or be damaging to the Company or any Subsidiary or their respective officers,
directors, employees, advisors, businesses or reputations. Notwithstanding the foregoing, nothing in this Agreement shall preclude Executive from making truthful statements or disclosures that are required by applicable law, regulation or legal
process. 

  

	5.	Non-solicitation. 

 During
the period beginning with the Effective Date and ending 18 months following the termination of Executive’s employment with the Company, Executive, whether acting on Executive’s own behalf or by, through or on behalf of any third party,
shall not (a) hire any employees of the Company or any Subsidiary, or recruit or solicit any such employees or encourage them to terminate their employment with the Company or any Subsidiary; (b) accept business from any customers of the
Company or any Subsidiary, or solicit or encourage any customers, joint venture partners or investors of the Company or any Subsidiary to terminate or diminish their relationship with the Company or any Subsidiary or to violate any agreement with
the Company or any Subsidiary. For purposes of subsection 5(a), an employee of the Company or any Subsidiary means any person who was employed by the Company or any Subsidiary within 180 days of such hiring, recruitment, solicitation or
encouragement. Executive agrees to make any employer with whom Executive becomes employed during the 18-month period following Executive’s termination with the Company aware of this non-solicitation obligation upon commencing employment with
such subsequent entity. 

  
 9 

	6.	Remedies. 

 In addition to
whatever other rights and remedies the Company may have at equity or in law, the Company (a) shall have the right to immediately terminate all payments and benefits due under this Agreement if Executive breaches any of the provisions contained
in Sections 4 or 5 above, and (b) shall have the right to seek injunctive relief in any court of competent jurisdiction if Executive breaches or threatens to breach any of the provisions contained in Sections 4 or 5 above. Executive
acknowledges that such a breach would cause irreparable injury and that money damages would not provide an adequate remedy for the Company; provided, however, the foregoing shall not prevent Executive from contesting the issuance of any such
injunction on the ground that no violation or threatened violation of Sections 4 or 5 has occurred. 
  

	7.	Effect of Agreement on Other Benefits and Obligations. 

 Except as specifically provided in this Agreement, the existence of this Agreement shall not be interpreted to preclude, prohibit or restrict the Executive’s participation in any other employee
benefit or other plans or programs in which he /she currently participates. Except as specifically provided in this Agreement, the terms of Sections 4 and 5 of this Agreement shall not be deemed to restrict or supersede any similar obligations
Executive may have to the Company or its subsidiaries under any other agreement. 
  

	8.	Not an Employment Agreement. 

 This Agreement is not, and nothing herein shall be deemed to create, a contract of employment between Executive and the Company. The Company may terminate the employment of Executive at any time and for
any reason, subject to the terms of any employment agreement between the Company and Executive that may then be in effect. 
  

	9.	Resolution of Disputes. 

Any controversy or claim arising out of or relating to this Agreement or any breach or asserted breach hereof or questioning the validity
and binding effect hereof arising under or in connection with this Agreement, other than seeking injunctive relief under Sections 4 or 5, shall be resolved by binding arbitration, to be held at an office closest to the Company’s principal
offices in accordance with the rules and procedures of the American Arbitration Association. Judgment upon the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof. Pending the resolution of any arbitration or
court proceeding, the company shall continue payment of all amounts and benefits due Executive under this Agreement. All reasonable costs and expenses of any arbitration or court proceeding (including fees and disbursements of counsel) shall be paid
on behalf of or reimbursed to Executive promptly by the Company; provided, however, that no reimbursement shall be made of such expenses if and to the extent the arbitrator(s) determine(s) that any of Executive’s litigation assertions or
defenses were in bad faith or frivolous. 
  

	10.	Assignability; Binding Nature. 

 This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors, heirs (in the case of Executive) and permitted assigns. No rights or obligations of the
Company under this Agreement may be assigned or transferred by the Company except that such rights or obligations may be assigned or transferred in connection with the sale or transfer of all or substantially all of the assets of the Company,
provided that the assignee or transferee is the successor to all or substantially all of the assets of the Company and such assignee or transferee assumes the liabilities, obligations and duties of the Company, as contained in this agreement, either
contractually or as a matter of law. The Company further agrees that, in the event of a sale or transfer of assets as described in the preceding sentence, it shall take whatever 

  
 10 

 
action it legally can in order to cause such assignee or transferee to expressly assume the liabilities, obligations and duties of the Company hereunder. No rights or obligations of Executive
under this Agreement may be assigned or transferred by Executive other than his/her, rights to compensation and benefits, which may be transferred only by will or operation of law, except as provided in Section 16 below. 

 

	11.	Representation. 

 The
Company represents and warrants that it is fully authorized and empowered to enter into this Agreement and that the performance of its obligations under this Agreement will not violate any agreement between it and any other person, firm or
organization. 
  

	12.	Amendment; Waiver; Code Section 409A. 

  

	 	(a)	No provision in this Agreement may be amended unless such amendment is agreed to in writing and signed by Executive and an authorized officer of the Company. No waiver
by either Party of any breach by the other Party of any condition or provision contained in this Agreement to be performed by such other Party shall be deemed a waiver of a similar or dissimilar condition or provision at the same or any prior or
subsequent time. Any waiver must be in writing and signed by Executive or an authorized officer of the Company, as the case may be. 

  

	 	(b)	Executive and Company agree that it is the intent of the parties that this Agreement not violate any applicable provision of, or result in any additional tax or penalty
under, Section 409A of the Code, as amended, and that to the extent any provisions of this Agreement do not comply with such Code Section 409A the parties will make such changes as are mutually agreed upon in order to comply with Code
Section 409A. In all events, to the extent required to avoid a violation of any of the applicable rules under Code Section 409A by reason of Code Section 409A(a)(2)(B)(i), payment of any amounts subject to Code Section 409A shall
be delayed until the relevant date of payment that will result in compliance with the rules of Code Section 409A(a)(2)(B)(i). 

  

	13.	Severability. 

 In the
event that any provision or portion of this Agreement shall be determined to be invalid or unenforceable for any reason, in whole or in part, the remaining provisions of this Agreement shall be unaffected thereby and shall remain in full force and
effect to the fullest extent permitted by law. 
  

	14.	Survivorship. 

 The
respective rights and obligations of the Parties hereunder shall survive any termination of Executive’s employment to the extent necessary to the intended preservation of such rights and obligations. 

 

	15.	Beneficiaries/References. 

Executive shall be entitled, to the extent permitted under any applicable law, to select and change a beneficiary or beneficiaries to
receive any compensation or benefit payable hereunder following Executive’s death by giving the Company written notice thereof. In the event of Executive’s death or a judicial determination of Executive’s incompetence, references in
this Agreement to Executive shall be deemed, where appropriate, to refer to Executive’s beneficiary, estate or other legal representative. 

  
 11 

	16.	Governing Law/Jurisdiction. 

 This Agreement shall be governed by and construed and interpreted in accordance with the laws of Rhode Island without reference to principles of conflict of laws. Subject to Section 6, the Company
and Executive hereby consent to the jurisdiction of any or all of the following courts for purposes of resolving any dispute under this Agreement: (i) the United States District Court for Rhode Island or (ii) any of the courts of the State
of Rhode Island. The Company and Executive further agree that any service of process or notice requirements in such proceeding shall be satisfied if the rules of such court relating thereto have been substantially satisfied. The Company and
Executive hereby waive, to the fullest extent permitted by applicable law, any objection which it or Executive may now or hereafter have to such jurisdiction and any defense of inconvenient forum. 

 

	17.	Notices. 

 Any notice
given to a Party shall be in writing and shall be deemed to have been given when delivered personally or sent by certified or registered mail, postage prepaid, return receipt requested, duly addressed to the Party concerned at the address indicated
below or to, such changed address as such Party may subsequently give such notice of: 
 If to CVS: 

CVS Pharmacy, Inc. 
 One CVS Drive 
 Woonsocket, RI 02895 

Attention: Corporate Secretary 
 If to Executive: 
 Per G.H. Lofberg 

63 East 92nd Street 
 New York, New York 10128 
 with a copy to: 

Laurence M. Moss, Esq. 
 Schulte Roth & Zabel LLP 
 919 Third Avenue 

New York, New York 10022 
  

	18.	Headings. 

 The headings
of the sections contained in this Agreement are for convenience only and shall not be deemed to control or affect the meaning or construction of any provision of this Agreement. 

  
 12 

	19.	Counterparts. 

 This
Agreement may be executed in two or more counterparts. 
 In WITNESS WHEREOF, the undersigned have executed this Agreement to be
effective as of the date first written above. 
  

			
	CVS Pharmacy, Inc.
		
	By:	 	 /s/ V. Michael Ferdinandi

		 	V. Michael Ferdinandi
		 	Senior Vice President, Human Resources
		
	Date:	 	

  

			
	Per G.H. Lofberg
	
	 /s/ Per G.H. Lofberg

	Executive Vice President, CVS Caremark Corporation and President, Pharmacy Benefit Services
		
	Date:	 	

  
 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]